214 related articles for article (PubMed ID: 34091114)
21. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
[TBL] [Abstract][Full Text] [Related]
22. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.
Bertaut A; Truntzer C; Madkouri R; Kaderbhai CG; Derangère V; Vincent J; Chauffert B; Aubriot-Lorton MH; Farah W; Mourier KL; Boidot R; Ghiringhelli F
Oncotarget; 2016 Oct; 7(43):70948-70958. PubMed ID: 27487142
[TBL] [Abstract][Full Text] [Related]
23. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
24. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
25. Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
Steidl E; Pilatus U; Hattingen E; Steinbach JP; Zanella F; Ronellenfitsch MW; Bähr O
PLoS One; 2016; 11(12):e0168113. PubMed ID: 28033329
[TBL] [Abstract][Full Text] [Related]
26. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
[TBL] [Abstract][Full Text] [Related]
28. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
Indraccolo S; Lombardi G; Fassan M; Pasqualini L; Giunco S; Marcato R; Gasparini A; Candiotto C; Nalio S; Fiduccia P; Fanelli GN; Pambuku A; Della Puppa A; D'Avella D; Bonaldi L; Gardiman MP; Bertorelle R; De Rossi A; Zagonel V
Clin Cancer Res; 2019 Mar; 25(6):1828-1837. PubMed ID: 30514778
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
30. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
31. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
32. Treatment response of bevacizumab combination chemotherapy in recurrent glioblastoma: A long-term retrospective study in Taiwan.
Huang YK; Lieu AS
Medicine (Baltimore); 2020 Feb; 99(8):e19226. PubMed ID: 32080119
[TBL] [Abstract][Full Text] [Related]
33. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
Sayour EJ; McLendon P; McLendon R; De Leon G; Reynolds R; Kresak J; Sampson JH; Mitchell DA
Cancer Immunol Immunother; 2015 Apr; 64(4):419-27. PubMed ID: 25555571
[TBL] [Abstract][Full Text] [Related]
34. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Batchelor TT; Mulholland P; Neyns B; Nabors LB; Campone M; Wick A; Mason W; Mikkelsen T; Phuphanich S; Ashby LS; Degroot J; Gattamaneni R; Cher L; Rosenthal M; Payer F; Jürgensmeier JM; Jain RK; Sorensen AG; Xu J; Liu Q; van den Bent M
J Clin Oncol; 2013 Sep; 31(26):3212-8. PubMed ID: 23940216
[TBL] [Abstract][Full Text] [Related]
35. Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.
Quillien V; Carpentier AF; Gey A; Avril T; Tartour E; Sejalon F; Campillo-Gimenez B; Vauleon E
Cancer Immunol Immunother; 2019 Jun; 68(6):871-882. PubMed ID: 30830269
[TBL] [Abstract][Full Text] [Related]
36. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
39. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.
Tamura R; Tanaka T; Ohara K; Miyake K; Morimoto Y; Yamamoto Y; Kanai R; Akasaki Y; Murayama Y; Tamiya T; Yoshida K; Sasaki H
Cancer Sci; 2019 Feb; 110(2):499-508. PubMed ID: 30467920
[TBL] [Abstract][Full Text] [Related]
40. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
Levin VA; Chan J; Datta M; Yee JL; Jain RK
J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
